Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084956 | 0.88 | BRD4 (0.43) | BRD4STING1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22894699 | 0.85 | CXCR4 (0.36) | CXCR4CYP2C19MAP4K1 | |
| SCHEMBL4035710 | 0.82 | BRD4 (0.43) | BRD4STING1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2084807 | 0.79 | BRD4 (0.44) | BRD4CXCR4STING1CYP3A4CYP2D6 | |
| SCHEMBL4037677 | 0.78 | BRD4 (0.43) | BRD4CXCR4STING1CYP3A4CYP2D6 | |
| SCHEMBL2083618 | 0.76 | NR1H2 (0.32) | MAP4K1 | |
| SCHEMBL22894783 | 0.76 | NR1H2 (0.32) | CXCR4 | |
| SCHEMBL2085737 | 0.75 | CXCR4 (0.60) | CXCR4CYP3A4L3MBTL1 | |
| SCHEMBL18764825 | 0.75 | ALDH1A1 (0.53) | BRD4BCHEL3MBTL1 | |
| SCHEMBL2341656 | 0.75 | MAPT (0.51) | BRD4MAP4K1BCHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | BRD4 2460/4885CXCR4 1/4885STING1 981/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | BRD4 1401/4885CXCR4 1/4885STING1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.